Ignite Creation Date:
2025-12-24 @ 11:21 PM
Ignite Modification Date:
2026-01-04 @ 10:01 PM
Study NCT ID:
NCT05206656
Status:
COMPLETED
Last Update Posted:
2022-11-23
First Post:
2021-12-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer
Sponsor:
Hunan Cancer Hospital
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
YYS-20200305
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None